A0001 Price List - nilotinib tartrate-Oncological Agents-Chronic Myelogenous Leukemia.xlsx
XLSX spreadsheet 46 KB Posted
- Solicitation number
- HT9402-25-Q-9304
- Issued by
-
Defense Health Agency
About this file
This is a Price List for the Department of Defense (DoD) Uniform Formulary Blanket Purchase Agreement (UF BPA) and Additional Discount Program (ADP) for Oncological Agents treating Chronic Myelogenous Leukemia, specifically focusing on nilotinib tartrate. The document is for the August 2025 Pharmacy and Therapeutics (P&T) Committee Meeting, with quotes due on July 30, 2025. The solicitation involves multiple newly approved drugs and requires manufacturers to submit pricing information across different formulary scenarios, including Uniform Formulary and Non-Formulary categories.
The price list includes detailed pricing appendices for ten newly approved drugs, with complex pricing mechanisms involving Federal Ceiling Price (FCP), Non-FAMP (Non-Federal Average Manufacturer Price), Wholesale Acquisition Cost (WAC), and various refund calculations. Notable terms include potential prior authorization requirements, step therapy addendum with grandfathering provisions, and a requirement for manufacturers to submit fully executed signature pages with quote information. The pricing documents are structured to support TRICARE retail refund calculations and provide flexibility for different formulary tiers and brand agent scenarios.
View the file
Other files
Show all 30
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
BPA
| UF BPA NDC Price List for the August 2025 DoD P&T Meeting | |||
| DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 |
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 |
| Formulary Notes | |||
| Class Note(s): Prior authorization may apply. |
Step Therapy Addendum: Grandfathering: a prior authorization process, may require all new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user. Unless otherwise noted, patients must have tried an agent in the class in the previous 180 days in order to be excluded from the prior authorization process.
Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 154ONCMG0UFNS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 154ONCMG0NFNS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 154ONCMG0UFNS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 154ONCMG0NFNS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #3 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 154ONCMG0UFNS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 154ONCMG0NFNS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 154ONCMG0UFNS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 154ONCMG0NFNS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #5 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 154ONCMG0UFNS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 154ONCMG0NFNS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 154ONCMG0UFNS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 154ONCMG0NFNS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 154ONCMG0UFNS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 154ONCMG0NFNS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 154ONCMG0UFNS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 154ONCMG0NFNS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #9 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 154ONCMG0UFNS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 154ONCMG0NFNS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #10 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 154ONCMG0UFNS1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 154ONCMG0NFNS1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
ADP (non-FAMP Discount)
| UF ADP Appendix for the August 2025 DoD P&T Meeting | |||
| DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 |
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 |
| Formulary Notes | |||
| Class Note(s): Prior authorization may apply. |
Step Therapy Addendum: Grandfathering: a prior authorization process, may require all new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user. Unless otherwise noted, patients must have tried an agent in the class in the previous 180 days in order to be excluded from the prior authorization process.
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 | |||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
ADP (WAC Discount)
| UF ADP Appendix for the August 2025 DoD P&T Meeting | |||
| DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 |
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 |
| Formulary Notes | |||
| Class Note(s): Prior authorization may apply. |
Step Therapy Addendum: Grandfathering: a prior authorization process, may require all new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to a new user. Unless otherwise noted, patients must have tried an agent in the class in the previous 180 days in order to be excluded from the prior authorization process.
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).
WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.
*The quoted WAC Discount percentage will remain static during the life of the agreement.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DOD Uniform Formulary Class: | ONCOLOGICAL AGENTS | P&T Committee Meeting: | August 6-7, 2025 | ||
| DOD Uniform Formulary Subclass: | CHRONIC MYELOGENOUS LEUKEMIA | Quotes due: | July 30, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 154ONCMG0T2NS1M | Tier 2 | 1 or more | |
| 154ONCMG0T3NS1M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
File details come from the government source that posted it. Updated .